|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||||||
| CURRENT ASSETS: | |||||||||||||||
| Cash | |||||||||||||||
| Restricted cash | |||||||||||||||
| Prepaid expenses | |||||||||||||||
| Receivable from Related Party | |||||||||||||||
| Deferred offering costs | |||||||||||||||
| Total current assets | |||||||||||||||
| Deferred acquisition costs | |||||||||||||||
| Cash and marketable securities held in Trust Account | |||||||||||||||
| Backstop Forward Purchase Agreement asset | |||||||||||||||
| Backstop Forward Purchase Agreement Asset | |||||||||||||||
| Investment in Virion | |||||||||||||||
| TOTAL ASSETS | |||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | |||||||||||||||
| CURRENT LIABILITIES: | |||||||||||||||
| Accounts payable and accrued expenses | |||||||||||||||
| Accrued liabilities - related party | |||||||||||||||
| Related Party | |||||||||||||||
| Total accrued liabilities - related party | |||||||||||||||
| Short term loan-related party | |||||||||||||||
| Short term loans, net of issuance costs | |||||||||||||||
| Short-term loans, net of issuance costs | |||||||||||||||
| Ayrton Note Purchase Option | |||||||||||||||
| SPA Warrant | |||||||||||||||
| Total current liabilities | |||||||||||||||
| Deferred Underwriting Commissions | |||||||||||||||
| Deferred Underwriting Commissions | |||||||||||||||
| SPA Warrant | |||||||||||||||
| Ayrton Note Purchase Option | |||||||||||||||
| NONCURRENT LIABILITIES | |||||||||||||||
| Fixed maturity consideration | |||||||||||||||
| Backstop put option liability | |||||||||||||||
| Total Noncurrent Liabilities | |||||||||||||||
| Virion contribution liability | |||||||||||||||
| Total liabilities | |||||||||||||||
| Class A common Stock subject to possible redemption, 10,500,000 shares (at redemption value of approximately $10.52 and $10.20 per share) at December 31, 2022 and 2021, respectively | |||||||||||||||
| STOCKHOLDERS’ DEFICIT: | |||||||||||||||
| Common stock, $0.0001 par value; 300,000,000 shares authorized as of March 31, 2025, and December 31, 2024, respectively,166,010,805 and 34,868,628 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively. | |||||||||||||||
| Common Class A | |||||||||||||||
| Common Class B | |||||||||||||||
| Additional paid-in capital | |||||||||||||||
| Accumulated deficit | |||||||||||||||
| Total stockholders’ deficit | |||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT |
Loading...
